These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 26616038)

  • 1. One versus two doses: What is the best use of vaccine in an influenza pandemic?
    Matrajt L; Britton T; Halloran ME; Longini IM
    Epidemics; 2015 Dec; 13():17-27. PubMed ID: 26616038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. H7N9: can H7N3 live-attenuated influenza vaccine be used at the early stage of the pandemic?
    Rudenko L; Isakova-Sivak I; Rekstin A
    Expert Rev Vaccines; 2014 Jan; 13(1):1-4. PubMed ID: 24308582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Considerations for the rapid deployment of vaccines against H7N9 influenza.
    Chua BY; Brown LE; Jackson DC
    Expert Rev Vaccines; 2014 Nov; 13(11):1327-37. PubMed ID: 25017993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An H5N1-based matrix protein 2 ectodomain tetrameric peptide vaccine provides cross-protection against lethal infection with H7N9 influenza virus.
    Leung HC; Chan CC; Poon VK; Zhao HJ; Cheung CY; Ng F; Huang JD; Zheng BJ
    Emerg Microbes Infect; 2015 Apr; 4(4):e22. PubMed ID: 26038770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tackling a novel lethal virus: a focus on H7N9 vaccine development.
    Isakova-Sivak I; Rudenko L
    Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28532182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
    Smith GE; Flyer DC; Raghunandan R; Liu Y; Wei Z; Wu Y; Kpamegan E; Courbron D; Fries LF; Glenn GM
    Vaccine; 2013 Sep; 31(40):4305-13. PubMed ID: 23891795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans.
    Overton ET; Goepfert PA; Cunningham P; Carter WA; Horvath J; Young D; Strayer DR
    Vaccine; 2014 Sep; 32(42):5490-5. PubMed ID: 25128802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
    Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F
    Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing the dose of pre-pandemic influenza vaccines to reduce the infection attack rate.
    Riley S; Wu JT; Leung GM
    PLoS Med; 2007 Jun; 4(6):e218. PubMed ID: 17579511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novavax’ H7N9 avian influenza VLP vaccine positive in Phase 1/2.
    Hum Vaccin Immunother; 2014; 10(11):3103-4. PubMed ID: 25789365
    [No Abstract]   [Full Text] [Related]  

  • 11. H7N9 pandemic preparedness: A large-scale production of a split inactivated vaccine.
    Adami EA; Chavez Rico SL; Akamatsu MA; Miyaki C; Raw I; de Oliveira D; Comone P; Oliveira RDN; Sarno de Oliveira ML; Estima Abreu PA; Takano CY; Meros M; Soares-Schanoski A; Lee Ho P
    Biochem Biophys Res Commun; 2021 Mar; 545():145-149. PubMed ID: 33550095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.
    Belshe RB; Frey SE; Graham IL; Anderson EL; Jackson LA; Spearman P; Edupuganti S; Mulligan MJ; Rouphael N; Winokur P; Dolor RJ; Woods CW; Walter EB; Chen WH; Turley C; Edwards KM; Creech CB; Hill H; Bellamy AR;
    JAMA; 2014 Oct; 312(14):1420-8. PubMed ID: 25291578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparing for a potential A(H7N9) pandemic: lessons from the deployment of A(H1N1) pandemic vaccines.
    Nguyen-Van-Tam JS; Sellwood C
    Expert Rev Vaccines; 2013 Aug; 12(8):825-8. PubMed ID: 23984955
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.
    Lin J; Zhang J; Dong X; Fang H; Chen J; Su N; Gao Q; Zhang Z; Liu Y; Wang Z; Yang M; Sun R; Li C; Lin S; Ji M; Liu Y; Wang X; Wood J; Feng Z; Wang Y; Yin W
    Lancet; 2006 Sep; 368(9540):991-7. PubMed ID: 16980114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.
    Mulligan MJ; Bernstein DI; Winokur P; Rupp R; Anderson E; Rouphael N; Dickey M; Stapleton JT; Edupuganti S; Spearman P; Ince D; Noah DL; Hill H; Bellamy AR;
    JAMA; 2014 Oct; 312(14):1409-19. PubMed ID: 25291577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparedness against pandemic influenza: Production of an oil-in-water emulsion adjuvant in Brazil.
    Akamatsu MA; Sakihara VA; Carvalho BP; de Paiva Abrantes A; Takano MAS; Adami EA; Yonehara FS; Dos Santos Carneiro P; Rico S; Schanoski A; Meros M; Simpson A; Phan T; Fox CB; Ho PL
    PLoS One; 2020; 15(6):e0233632. PubMed ID: 32492039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
    Levie K; Leroux-Roels I; Hoppenbrouwers K; Kervyn AD; Vandermeulen C; Forgus S; Leroux-Roels G; Pichon S; Kusters I
    J Infect Dis; 2008 Sep; 198(5):642-9. PubMed ID: 18576945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does vaccine dose predict response to the monovalent pandemic H1N1 influenza a vaccine in children with acute lymphoblastic leukemia? A single-centre study.
    Leahy TR; Smith OP; Bacon CL; Storey L; Lynam P; Gavin PJ; Butler KM; O'Marcaigh AS
    Pediatr Blood Cancer; 2013 Oct; 60(10):1656-61. PubMed ID: 23682005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal vaccine allocation for the early mitigation of pandemic influenza.
    Matrajt L; Halloran ME; Longini IM
    PLoS Comput Biol; 2013; 9(3):e1002964. PubMed ID: 23555207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. H7N3 live attenuated influenza vaccine has a potential to protect against new H7N9 avian influenza virus.
    Rudenko L; Isakova-Sivak I; Donina S
    Vaccine; 2013 Oct; 31(42):4702-5. PubMed ID: 23988294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.